AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today preliminary results from two prospective studies demonstrated that AnPac Bio’s Cancer Differentiation Analysis (CDA) based tests have the ability to assess the risks of cancer occurrence.
In a study of follow-up phone consultations commenced in 2017, over 13,000 individuals (including individuals tested with high risk, medium risk and low risk CDA scores) had provided the company with substantive feedback regarding their health conditions and disease development as of July 31, 2020, and among them, there had been diagnosed over 190 cancer cases, over 900 pre-cancer cases, and 700 disease cases, with higher predictive values being statistically significantly higher from individuals with higher CDA scores. In another prospective study that began last year with close to 2,000 individuals of 65 years old or above, 10 cancer cases have been confirmed. The above results demonstrated that CDA technology is capable of assessing pre-cancer and early stage cancer risks.
AnPac Bio’s CEO, Dr. Chris Yu, commented, “while there are a number of cancer screening technologies aimed at detecting cancer early, only a limited number of them have proven the ability to do so, with many of them still in the R&D phase. AnPac Bio’s CDA technology has been demonstrated, in both retrospective and prospective studies, to be able to detect pre-cancer disease and early stage cancer signals with statistical significance. We are proud to be saving lives.”
Dr. Chris Yu continued, “Cancer screening markets in both US and China are significant and growing. The current global cancer diagnostics market size is $144 Billion and expected to grow up to $249 Billion by 2026. We believe that AnPac Bio is well positioned to capture these markets with our innovative technology, significant patent portfolio, one of the world’s largest clinical sample size among companies offering next-generation early cancer screening and detection technologies, and extensive experience in cancer screening and detection.”
About AnPac Bio
AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 128 issued patents as of June 30, 2020. With two certified clinical laboratories in China and one CLIA and CAP accredited clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests. According to Frost & Sullivan, AnPac Bio ranked third worldwide and first in China among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection, based on approximately 41,700 clinical samples as at May 2020. AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity.
For more information, please visit: https://www.Anpacbio.com.
